Crossover comparison of benoxaprofen and naproxen in rheumatoid arthritis.
This multicenter double-blind clinical trial compared the efficacy and safety of benoxaprofen and naproxen in the treatment of rheumatoid arthritis. The studies followed a crossover design which provided 6 wk therapy with each of the 2 study drugs. Benoxaprofen at a single daily dose of 600 mg compared favorably to naproxen, 750 mg, administered in 2 equally divided doses. All efficacy results indicated slightly more improvement with benoxaprofen although the difference between the 2 drugs was not significant. Side effects were generally mild and only 1 patient discontinued benoxaprofen therapy because of a reactivation of a duodenal ulcer.
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001583:Benzoxazoles / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001799:Blood Sedimentation; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000627:therapeutic use*; D010349:Patient Compliance; D011422:Propionates / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D001583:Benzoxazoles; D011422:Propionates; C011677:benoxaprofen; D009288:Naproxen